A Dara1,2, B B Mook3, J K Doorduijn4, M J van den Bent5, A G Dinmohamed4,6,7, J E C Bromberg5. 1. Department of Neurology, Haga Teaching Hospital, Den Haag, The Netherlands. a.dara@rdgg.nl. 2. Department of Neurology, Reinier de Graaf Hospital, Delft, The Netherlands. a.dara@rdgg.nl. 3. Department of Neurology, Haga Teaching Hospital, Den Haag, The Netherlands. 4. Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. 5. Department of Neuro-oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. 6. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 7. Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
Abstract
INTRODUCTION: Central nervous system (CNS) involvement, especially involvement of the cerebrospinal fluid (CSF), is common in several haematological malignancies. Intrathecal (IT) chemotherapy can be used to manage CSF involvement. METHODS: Here we evaluated the effectiveness of IT chemotherapy among 80 patients with haematological malignancies and CSF localization who were treated with IT chemotherapy from 2001 to 2012. RESULTS: The majority of patients was diagnosed with diffuse large B-cell lymphoma (26%) or acute lymphoblastic leukaemia/lymphoblastic lymphoma (19%). After first-line IT chemotherapy, which mainly consisted of methotrexate (MTX) and corticosteroids, CSF complete response (CSF CR) was achieved in 76% of patients. 91% reached CSF CR when including second-line IT-chemotherapy. Clinical response was documented in 75%. Although most patients were additionally treated with systemic chemotherapy, response rate did not differ between patients treated with CNS-penetrating and CNS-non-penetrating drugs. CNS progression/relapse occurred in 40% of patients with median progression-free survival of 12.2 months. The median overall survival was 18.3 months; 55% of the patients died during follow-up. CONCLUSIONS: Our analysis shows a high response rate after first-line IT chemotherapy, but also a relatively high progression/relapse percentage.
INTRODUCTION: Central nervous system (CNS) involvement, especially involvement of the cerebrospinal fluid (CSF), is common in several haematological malignancies. Intrathecal (IT) chemotherapy can be used to manage CSF involvement. METHODS: Here we evaluated the effectiveness of IT chemotherapy among 80 patients with haematological malignancies and CSF localization who were treated with IT chemotherapy from 2001 to 2012. RESULTS: The majority of patients was diagnosed with diffuse large B-cell lymphoma (26%) or acute lymphoblastic leukaemia/lymphoblastic lymphoma (19%). After first-line IT chemotherapy, which mainly consisted of methotrexate (MTX) and corticosteroids, CSF complete response (CSF CR) was achieved in 76% of patients. 91% reached CSF CR when including second-line IT-chemotherapy. Clinical response was documented in 75%. Although most patients were additionally treated with systemic chemotherapy, response rate did not differ between patients treated with CNS-penetrating and CNS-non-penetrating drugs. CNS progression/relapse occurred in 40% of patients with median progression-free survival of 12.2 months. The median overall survival was 18.3 months; 55% of the patients died during follow-up. CONCLUSIONS: Our analysis shows a high response rate after first-line IT chemotherapy, but also a relatively high progression/relapse percentage.
Authors: Upendra Hegde; Armando Filie; Richard F Little; John E Janik; Nicole Grant; Seth M Steinberg; Kieron Dunleavy; Elaine S Jaffe; Andrea Abati; Maryalice Stetler-Stevenson; Wyndham H Wilson Journal: Blood Date: 2004-09-09 Impact factor: 22.113
Authors: Rosanna Parasole; Fara Petruzziello; Chiara Messina; Elena Barisone; Andrea Pession; Franco Locatelli; Concetta Micalizzi; Simone Cesaro; Anna Maria Testi; Antonia De Matteo; Stefania Varotto; Massimo Berger; William Morello; Giuseppe Menna; Vincenzo Poggi Journal: Leuk Lymphoma Date: 2014-08-04
Authors: J E C Bromberg; D A Breems; J Kraan; G Bikker; B van der Holt; P Sillevis Smitt; M J van den Bent; M van't Veer; J W Gratama Journal: Neurology Date: 2007-05-15 Impact factor: 9.910